American Regent vs. Long Grove: Selenium Patent Suit Ends in Swift Voluntary Dismissal in Delaware
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | American Regent, Inc. v. Long Grove Pharmaceuticals, LLC |
| Case Number | 1:24-cv-00825 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | July 16, 2024 – August 19, 2024 34 days |
| Outcome | Plaintiff Voluntary Dismissal (Without Prejudice) |
| Patents at Issue | |
| Accused Products | Long Grove Selenious Acid Formulations (Eq. 600 mcg, 60 mcg, 12 mcg Selenium) |
Case Overview
The Parties
⚖️ Plaintiff
New York-based specialty pharmaceutical company and a subsidiary of Luitpold Pharmaceuticals. American Regent has a well-established portfolio of injectable pharmaceutical products, including micronutrient formulations used in parenteral nutrition.
🛡️ Defendant
Pharmaceutical company offering competing selenium formulations. Its accused products directly mirror the concentration profiles of American Regent’s products, suggesting Long Grove entered the market with a parallel product line targeting the same clinical applications.
The Patent at Issue
This case involved U.S. Patent No. US11998565B2 (Application No. US18/124391), covering selenious acid formulations for parenteral selenium supplementation. Selenious acid is a critical trace element administered intravenously to patients receiving total parenteral nutrition (TPN). The patent’s claims likely cover specific concentration thresholds, formulation parameters, or manufacturing processes that distinguish the covered products from prior art alternatives.
- • US11998565B2 — Selenious acid formulations for intravenous selenium supplementation.
Developing a similar pharmaceutical product?
Check if your formulation might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was terminated by voluntary dismissal without prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i). No damages were awarded. No injunctive relief was granted or denied. No judicial ruling on the merits was issued. Because the dismissal was without prejudice, American Regent retains the right to refile the same claims against Long Grove in a future action, subject to applicable statutes of limitations and any procedural constraints.
Note: Specific settlement terms, licensing agreements, or underlying commercial arrangements, if any, were not disclosed in the public record.
Key Legal Issues
The strategic calculus behind a Rule 41(a)(1)(A)(i) dismissal at this juncture is instructive. This mechanism is only available prior to the defendant’s answer or summary judgment motion — meaning American Regent acted swiftly and deliberately. Possible explanations include:
- Out-of-court resolution: Parties may have reached a licensing agreement or consent arrangement off the docket.
- Patent prosecution development: Activity on Application No. US18/124391 may have warranted reassessment of claim scope before proceeding.
- Tactical repositioning: Plaintiff may have identified a stronger legal theory, additional patents, or preferred venue for a subsequent action.
- Commercial negotiation: A business resolution may have rendered continued litigation unnecessary.
While this case produced no precedential ruling, it highlights the increasing use of voluntary dismissal as a strategic tool in ANDA-adjacent pharmaceutical patent litigation.
Freedom to Operate (FTO) Analysis for Pharmaceutical Formulations
This case highlights critical IP risks in specialty pharmaceutical formulation design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in the selenious acid technology space
- See which companies are most active in parenteral nutrition patents
- Understand claim construction patterns for similar formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical technology or product.
- Input your product description or technical formulation features
- AI identifies potentially blocking patents in clinical nutrition
- Get actionable risk assessment report for your IP team
High Risk Area
Identical selenious acid concentration profiles
1 Key Patent
US11998565B2 at issue
Design-Around Options
Potential for formulation tweaks
✅ Key Takeaways
Rule 41(a)(1)(A)(i) voluntary dismissal without prejudice is a tactically viable tool when litigation timing requires adjustment post-filing.
Search related case law →A complaint filed and voluntarily dismissed without prejudice can serve legitimate strategic purposes, including signaling enforcement intent or initiating licensing discussions.
Explore litigation strategies →Frequently Asked Questions
The case involved U.S. Patent No. US11998565B2 (Application No. US18/124391), covering selenious acid formulations used for intravenous selenium supplementation.
American Regent voluntarily dismissed all claims without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(i) after 34 days. No public explanation was provided; potential reasons include out-of-court resolution, licensing negotiations, or strategic repositioning.
Yes. A without-prejudice dismissal preserves American Regent’s right to refile the same claims against Long Grove, subject to applicable statutes of limitations.
A ‘without prejudice’ dismissal allows the plaintiff to refile the lawsuit later. In pharma patent litigation, this can be a strategic move to re-evaluate claims, pursue licensing, or consolidate litigation efforts, offering flexibility without conceding on the merits.
Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in the pharma sector.
References
- PACER — Case No. 1:24-cv-00825, D. Del.
- USPTO Patent Center — US11998565B2
- Cornell Legal Information Institute — Fed. R. Civ. P. 41
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.